Evidence review

Tesamorelin and Visceral Abdominal Fat: What Human Trials Show on GH Axis Effects

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 3 min read

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tesamorelin might help you

Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

Tesamorelin → GH axis / visceral fat

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 2
Claims tagged human evidence: 4
Claims tagged preclinical (animal/lab): 0
Claims tagged anecdotal: 2
Reddit posts catalogued: 1
X posts catalogued: 1
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 4

Quantified confidence (this ledger): 0.56 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Effects of tesamorelin on visceral fat in HIV patients (source s1)

Pooled Phase 3 data showing visceral fat reduction and reversal on discontinuation.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Effects of tesamorelin on visceral fat in HIV patients

Pooled Phase 3 data showing visceral fat reduction and reversal on discontinuation.

2026-06-29 23:20s1 · #9fbc7bc759ef

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV (source s2)

Randomized trial demonstrating liver fat reduction.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV

Randomized trial demonstrating liver fat reduction.

2026-06-29 23:20s2 · #e9cea640fc0b

What people say on Reddit

Tesamorelin Belly Fat Reduction — Reddit, r/USPeptides (source s3)

User reports on visceral fat loss and rebound.

r/USPeptides· u/[deleted]

Tesamorelin Belly Fat Reduction

It mainly reduces visceral fat via GH/IGF-1... the visceral fat lost on tesamorelin tends to come back pretty fast after stopping.

⬆ • ⬇⤴ Share

2026-06-29 23:20s3 · #1de5f44cc054

What people say on X

Tesamorelin note on X — X (source s4)

X post summarizing trial reversal data.

peptigrity @peptigrity

Two Phase 3 placebo-controlled trials in 800+ HIV patients showed a real reduction in visceral fat... the effect reversed when people stopped.

Jun 29, 2026

2026-06-29 23:20s4 · #bfa509652e40

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 4 sources · swipe →chain bfa509652e40 · verify chain · provenance

1 / 4

PubMed.gov

Study

Effects of tesamorelin on visceral fat in HIV patients

Pooled Phase 3 data showing visceral fat reduction and reversal on discontinuation.

2026-06-29 23:20s1 · #9fbc7bc759ef

PubMed.gov

Study

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV

Randomized trial demonstrating liver fat reduction.

2026-06-29 23:20s2 · #e9cea640fc0b

r/USPeptides· u/[deleted]

Tesamorelin Belly Fat Reduction

It mainly reduces visceral fat via GH/IGF-1... the visceral fat lost on tesamorelin tends to come back pretty fast after stopping.

⬆ • ⬇⤴ Share

2026-06-29 23:20s3 · #1de5f44cc054

peptigrity @peptigrity

Two Phase 3 placebo-controlled trials in 800+ HIV patients showed a real reduction in visceral fat... the effect reversed when people stopped.

Jun 29, 2026

2026-06-29 23:20s4 · #bfa509652e40

Evidence ledger 6 · tier-ranked · API

human

No published human trials examine tesamorelin for direct gut barrier, microbiome, or non-HIV abdominal conditions.

humanlow confidence

Two Phase 3 trials in 816 HIV patients showed 15-18% visceral adipose tissue reduction after 26 weeks of 2 mg daily tesamorelin.

sources: s1

humanlow confidence

Visceral fat reduction reversed when treatment stopped in extension phases.

sources: s1

humanlow confidence

A 48-patient randomized trial found modest liver fat reduction with tesamorelin alongside visceral fat loss.

sources: s2

anecdotallow confidence

Reddit users report targeted deep belly fat loss with quick return after stopping.

sources: s3

1 more ranked claim

anecdotal0.22low confidence

X posts note FDA approval history and reversal of visceral fat loss upon discontinuation.

grok/grok-4.3

Provides platform-specific anecdotal layer.

sources: s4

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:20

Tesamorelin and Visceral Abdominal Fat: What Human Trials Show on GH Axis Effects · 6 claims · 4 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Gut
Slug: tesamorelin-gut
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],"degene

it output

{
  "slug": "tesamorelin-gut",
  "title": "Tesamorelin and Visceral Abdominal Fat: What Human Trials Show on GH Axis Effects",
  "body": "## What's breaking down\n\nExcess visceral fat accumulates around abdominal organs, including areas near the gut. This layer sits deep and can press on digestive structures. Growth hormone pulses often decline with age or certain conditions, shifting fat storage toward visceral deposits rather than subcutaneous. If visceral fat builds faster than the body clears it, abdominal girth increases and metabolic stress on nearby tissues rises. Tesamorelin targets the GH axis to address this specific deposition pattern.\n\n## Why Tesamorelin might help you\n\n1. Tesamorelin acts as a growth hormone-releasing hormone analog. It stimulates the pituitary to release more of your own growth hormone in pulses.\n2. Higher pulsatile GH increases IGF-1 and shifts fat metabolism away from visceral storage.\n3. Therefore for you: If visceral fat around abdominal organs forms part of your picture, the compound is discussed because it supports selective reduction in that compartment rather than blanket suppression of appetite or inflammation.\n4. Reduced visceral fat lowers mechanical pressure on abdominal contents and improves lipid markers in studied populations.\n5. The effect occurs without major loss of subcutaneous fat or lean mass in the key trials.\n\n##

97342f6cc9a9be80

Machine verification: /api/articles/tesamorelin-gut/contributions

Ask this article · 8 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human trials examine tesamorelin for direct gut barrier, microbiome, or non-HIV abdominal conditions."?

ask tesamorelin-gut claim c4 · paste includes §SELF

What does the ledger say about this (human tier): "Two Phase 3 trials in 816 HIV patients showed 15-18% visceral adipose tissue reduction after 26 weeks of 2 mg daily tesamorelin."?

ask tesamorelin-gut claim c1 · paste includes §SELF

What does the ledger say about this (human tier): "Visceral fat reduction reversed when treatment stopped in extension phases."?

ask tesamorelin-gut claim c2 · paste includes §SELF

What does the ledger say about this (human tier): "A 48-patient randomized trial found modest liver fat reduction with tesamorelin alongside visceral fat loss."?

ask tesamorelin-gut claim c3 · paste includes §SELF

What does the ledger say about this (anecdotal tier): "Reddit users report targeted deep belly fat loss with quick return after stopping."?

ask tesamorelin-gut claim c5 · paste includes §SELF

What does the ledger say about this (anecdotal tier): "X posts note FDA approval history and reversal of visceral fat loss upon discontinuation."?

ask tesamorelin-gut claim c6 · paste includes §SELF

Summarize this reddit report and how it should weigh: "User reports on visceral fat loss and rebound."

ask tesamorelin-gut source s3 · paste includes §SELF

Summarize this x report and how it should weigh: "X post summarizing trial reversal data."

ask tesamorelin-gut source s4 · paste includes §SELF

What's breaking down

Why Tesamorelin might help you

How these fit together

What the evidence actually shows

What scientists say

Effects of tesamorelin on visceral fat in HIV patients (source s1)

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV (source s2)

What people say on Reddit

What people say on X

Connected articles

Related articles